Impact of dosing on treatment with TNF inhibitors: Managing dose adjustment

Clinical and Experimental Rheumatology

Volumn 28, Issue 3 SUPPL. 59, 2010, Pages

  Combe, B ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Dose escalation; Dosing; Rheumatoid arthritis; TNF inhibitors

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL PRACTICE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; DRUG ANTAGONISM;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956415622     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
2. KLARESKOG L, VAN DER HD, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
3. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
4. KEYSTONE E, VAN DER HEIJDE D, MASON D et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008; 58: 3319-29.
5. SMOLEN JS, LANDEWE R, MEASE P et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
6. STRAND V, KEININGER DL, KAVANAUGH A: Certolizumab pegol (CZP) induces rapid and sustained clinically meaningful improvements in physical function and health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA): The RAPID 1 and 2 randomised clinical trials (RCTS). Ann Rheum Dis 2008; 67: 331.
7. KAVANAUGH A, SMOLEN J, EMERY P et al.: Certolizumab pegol with methotrexate improves home and workplace productivity and social activities in patients with active rheumatoid arthritis. Arthritis Care Res 2009; in press.
8. COMBE B, LANDEWE R, LUKAS C et al.: EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45.
9. SAAG KG, TENG GG, PATKAR NM et al: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
10. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
11. Remicade [prescribing information]. Malvern, PA: Centocor Ortho Biotech Inc.; 2009.
12. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253-9.
13. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
14. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
15. KEYSTONE EC, SCHIFF MH, KREMER JM et al.: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63.
16. Enbrel [prescribing information]. Thousand Oaks, CA: Immunex Corporation; 2009.
17. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
18. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
19. VAN DE PUTTE LB, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
20. Humira [prescribing information]. North Chicago, IL: Abbott Laboratories; 2009.
21. KEYSTONE EC, GENOVESE MC, KLARESKOG L et al.: Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-96.
22. Simponi [prescribing Information]. Horsham, PA: Centocor Ortho Biotech Inc.; 2009.
23. FLEISCHMANN R, VENCOVSKY J, VAN VOLLENHOVEN R et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11.
24. BENDTZEN K, GEBOREK P, SVENSON M, LARSSON L, KAPETANOVIC MC, SAXNE T: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-9.
25. BARTELDS GM, WIJBRANDTS CA, NURMOHAMED MT et al.: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
26. GOEKOOP-RUTTERMAN YP, VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
27. LUTT JR, DEODHAR A: Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008; 68: 591-606.
28. Remicade Summary of Product Characteristics. Leiden, The Netherlands: Centocor B.V.; 2009.
29. JOHNSEN AK, SCHIFF MH, MEASE PJ et al.: Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006; 33: 659-64.
30. WEINBLATT ME, SCHIFF MH, RUDERMAN EM et al: Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58: 1921-30.
31. Cimzia [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
32. GILBERT TD, JR., SMITH D, OLLENDORF DA: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004; 5: 36.
33. ETEMAD L, YU EB, WANKE LA: Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005; 18: 21-7.
34. ARIZA-ARIZA R, NAVARRO-SARABIA F, HERNANDEZ-CRUZ B, RODRIGUEZ-ARBOLEYA L, NAVARRO-COMPAN V, TOYOS J: Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-32.
35. RAHMAN MU, STRUSBERG I, GEUSENS P et al.: Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1233-8.
36. MOOTS RJ et al.: Dose escalation accounts for differences in cost of care in 739 patients with rheumatoid arthritis (RA) treated with anti-TNF agents (ATAs): results from the DART study. Presented at: EULAR 2008; June 11-14, 2008; Paris, France. Abstract FRI0139.
37. WU E, CHEN L, BIRNBAUM H, YANG E, CIFALDI M: Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008; 24: 2229-40.
38. BOMBARDIERI S, RUIZ AA, FARDELLONE P et al.: Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-9.
39. SMOLEN JS, KAY J, DOYLE MK et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
40. REMY A, AVOUAC J, GOSSEC L, COMBE B: Clinical pertinence of the switch to a second TNF inhibitor after failure of a first one in rheumatoid arthritis: a systematic literature review and meta-analysis [abstract]. Ann Rheum Dis 2009; 68 (Suppl. 3): 230.
41. ERICKSON AR, MIKULS TR: Switching anti-TNF-alpha agents: what is the evidence? Curr Rheumatol Rep 2007; 9: 416-20.
42. KEYSTONE EC: Switching tumor necrosis factor inhibitors: an opinion. Nat Clin Pract Rheumatol 2006; 2: 576-7.
43. SCOTT DL, COPE A: New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? Ann Rheum Dis 2009; 68: 767-9.
44. BULLANO MF, MCNEELEY BJ, YU YF et al.: Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006; 19: 47-53.
45. European Medicines Agency, www.emea.europe.eu/humandocs/PDFs/EPAR/humira/ EMEA-H-481-II-21-AR.pdf. Accessed July 28, 2009.